CTOs on the Move

ImmusanT

www.immusant.com

 
ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.immusant.com
  • One Kendall Square Suite B2004
    Cambridge, MA, MA USA 02139
  • Phone: 617.299.8399

Executives

Name Title Contact Details

Funding

ImmusanT raised $40M on 11/14/2017

Similar Companies

Bruker

Bruker is a Goleta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oregon Bioscience

Oregon Bioscience Association (@OregonBio) members are involved in cutting edge research and development of innovative health care, agricultural and environmental bio technologies. Our corporate members range from entrepreneurial start ups developing a first product to large multinationals. We also represent the state`s biotech research institutions, service providers to the industry and academic centers of learning. A unified voice for the Oregon bioscience community the Oregon Bio: * Represents the bioscience research to commercialization process * Helps to accelerate the growth of the biosciences industry in all parts of Oregon * Enhances the state`s bioscience business and research climate * Helps attract and retain bioscience talent and companies. * Vigorously works to improve the quality of the bioscience workforce * Partners with government at all levels to achieve its goals.

Chiral Quest

Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tripos

Tripos, L.P. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.